Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, asc... (original) (raw)
Related papers
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks
JAMA Neurology
8 Evaluating avalglucosidase alfa for the management of late-onset Pompe disease.
Expert Review on Neurotherapeutics, 2024
Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease
Neuromuscular Disorders, 2014
Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review
Journal of Neurology, 2013
A Systematic Review and Meta-Analysis of Enzyme Replacement Therapy in Late-Onset Pompe Disease
Journal of Clinical Medicine, 2021
Journal of Neurology
Neuromuscular Disorders, 2016
A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
New England Journal of Medicine, 2010
Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report
Laura Giordano, Alessia Cerutti
Journal of Inherited Metabolic Disease, 2010
Enzyme replacement therapy for Pompe disease
Current neurology and neuroscience reports, 2012
Genetics in Medicine
Corrado Angelini, Corrado I Angelini
Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study
Neurology, 2017
The impact of interrupting enzyme replacement therapy in late-onset Pompe disease
Journal of Neurology, 2021
Journal of Inherited Metabolic Disease, 2013
Impact of enzyme replacement therapy on survival in adults with Pompe disease
BMC Musculoskeletal Disorders, 2013
Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease
The FASEB Journal, 2014
Orphanet Journal of Rare Diseases, 2013
Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease
Neurology, 2019
Long-term efficacy of alglucosidase alfa in late-onset Pompe disease
Molecular Genetics and Metabolism, 2017
Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease
Molecular genetics and metabolism reports, 2017
Orphanet Journal of Rare Diseases, 2012
Cardiovascular Abnormalities in Late Onset Pompe Disease and Response to Enzyme Replacement Therapy
Genetics in medicine: …, 2011
Enzyme Replacement Therapy for Infantile-Onset Pompe Disease: Curse or Cure?
Neurology, 2008
Enzymatic replacement therapy in patients with late-onset Pompe disease – 6-Year follow up
Neurologia i Neurochirurgia Polska, 2018
Open Journal of Clinical Diagnostics, 2019
Molecular basis and clinical management of Pompe disease
Cardiogenetics, 2013
Pompe disease: what are we missing?
Annals of Translational Medicine
Enzyme therapy for Pompe disease: from science to industrial enterprise
European Journal of Pediatrics, 2002
Brain and Development, 2012